About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT06868576

PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial

The aim of this study is to compare the efficacy and safety of Progestin-Primed Ovarian Stimulation (PPOS) protocol versus the fixed GnRH antagonist protocol in expected normal responder patients unde...

Lead sponsor: Kasr El Aini Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Kasr El Aini Hospital

In this prospective, non-inferiority trial, we will compare the efficacy and safety of the GnRH antagonist and PPOS protocols in 328 infertile women undergoing ICSI in Kasr Al-Ainy IVF department, Cairo University, Egypt. Before the trial, investigators were required to provide all information related to the clinical trial, including the possible benefits and risks, other therapeutic choices and the right to withdraw, via a written consent. After being provided with sufficient time to decide whether to participate and the opportunity to ask questions, all participants were required to provide written informed consent before study inclusion.

Age

18 - 39 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•• Women who had history of infertility for ≥1 year.
•* Women whose age \<40 years old by the end of the study.
•* Anti-Mullerian hormone \> 1.2 ng/ml.
•* Antral follicle count ≥ 5.

Exclusion Criteria

•• Age ≥ 40 years old.
•* Women who are diagnosed as polycystic ovarian syndrome.
•* Women with endometriosis stage 3 or 4.
•* Documented previous IVF/ICSI cycles with no oocytes retrieved.
•* Women with contraindications to controlled ovarian stimulation.
•* Patients who refuse to share in the study.

Related studies

ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in Adolescence

NCT07456631 · Social Anxiety Disorder (SAD), Oppositional Defiant Disorder

RECRUITINGPhase 1/2

Pathways 2 Success

NCT06831123 · Conduct Disorder, Oppositional Defiant Disorder

Enrolling By InvitationNA

Multifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes

NCT07409792 · Infertility, Female, Anxiety, and more

Personalizing Psychosocial Intervention for Children With Disruptive Behaviour

NCT07495683 · Behavioural Disorder, Disruptive Behavior Disorder, and more

On-line Treatment for Conduct Problems

NCT01822392 · Conduct Disorder, Oppositional Defiant Disorder

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 11, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment328

Start dateJan 2023

Last updatedMar 11, 2025

Condition

PPOS GnRH Antagonist Assisted Reproductive Techniques

Locations shown

Ciro University Kasr Alainy OBGYN Hospital

Cairo, Alquahira

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 11, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions